Mostrar el registro sencillo del ítem
dc.contributor.author | Epaillard, Nicolas | |
dc.contributor.author | Parent, Pauline | |
dc.contributor.author | Loriot, Yohann | |
dc.contributor.author | Lavaud, Pernelle | |
dc.contributor.author | Vera-Cea, E-B. | |
dc.contributor.author | Martinez-Chanza, Nieves | |
dc.contributor.author | Rodriguez-Vida, Alejo | |
dc.contributor.author | Dumont, Clement | |
dc.contributor.author | Lozano, Rebeca | |
dc.contributor.author | Llácer, Casilda | |
dc.contributor.author | Ratta, Raffaele | |
dc.contributor.author | Oudard, Stephane | |
dc.contributor.author | Thibault, Constance | |
dc.contributor.author | Auclin, Edouard | |
dc.date.accessioned | 2024-02-19T15:28:25Z | |
dc.date.available | 2024-02-19T15:28:25Z | |
dc.date.issued | 2021-05-20 | |
dc.identifier.other | http://hdl.handle.net/10668/3894 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/18352 | |
dc.description.abstract | Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers. Materials: Multicenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Between 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type. Conclusion: Chemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature. | |
dc.language.iso | eng | |
dc.publisher | Frontiers Media | |
dc.type.hasVersion | VoR | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Urinary bladder neoplasms | |
dc.subject | Variant histology | |
dc.subject | Drug therapy | |
dc.subject | Immunotherapy | |
dc.subject | Mortality | |
dc.subject | Neoplasias de la vejiga urinaria | |
dc.subject | Quimioterapia | |
dc.subject | Inmunoterapia | |
dc.subject | Mortalidad | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Female | |
dc.subject.mesh | Carcinoma, Transitional Cell | |
dc.subject.mesh | Urinary Bladder Neoplasms | |
dc.subject.mesh | Platinum | |
dc.subject.mesh | Confidence Intervals | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Drug Therapy | |
dc.title | Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study | |
dc.type | research article | |
dc.rights.license | Attribution 4.0 International | * |
dc.identifier.pubmedID | 34094973 | es_ES |
dc.identifier.doi | 10.3389/fonc.2021.671969 | |
dc.identifier.e-issn | 2234-943X | es_ES |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fonc.2021.671969/full | es |
dc.identifier.journal | Frontiers in Oncology | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.contributor.authoraffiliation | [Epaillard,N; Oudard,S; Thibault,C; Auclin E] Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, France. [Parent,P; Loriot,Y; Lavaud,P] Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France. [Vera-Cea,E-B; Rodriguez-Vida,A] Medical Oncology Department, Hospital del Mar, IMIM Research Institute, Barcelona, Spain. [Martinez-Chanza,N] Medical Oncology Departments, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. [Dumont,C] Medical Oncology Department, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France. [Lozano,R] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain. [Lozano,R; Llácer,C] Genitourinary Oncology Translational Research Group, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain. [Ratta,R] Medical Oncology Department, Hopital Foch, Suresnes, France. |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |